Literature DB >> 17352235

Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread.

Marek Bebenek1, Danuta Duś, Joanna Koźlak.   

Abstract

BACKGROUND: Bones belong to the most frequent localizations of breast cancer metastases. Several studies on female breast malignancies have indicated that Fas/Fas-ligand status may have a significant impact on survival. Hence, the aim of our study was to determine if these molecules might serve as the predictors of skeletal dissemination in radically-treated breast cancer patients. PATIENTS AND METHODS: Tumor samples from 147 radically-treated breast cancer patients were studied immunohistochemically for Fas/Fas-ligand expression.
RESULTS: Both Fas and Fas-ligand expression in the primary tumor were considerably less frequent among breast cancer patients with bone metastases compared to women without skeletal spread. Moreover, negative staining for Fas or the lack of Fas-ligand expression proved to be significant predictors for the survival free from bone metastases under univariate analysis.
CONCLUSION: Our results suggest that the probability of bone metastases may be assessed on the basis of Fas/Fas-ligand expression in primary breast cancer. Consequently, their determination seems crucial for further prognosis and determination of adjuvant treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17352235

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.

Authors:  Nadezhda V Koshkina; Krithi Rao-Bindal; Eugenie S Kleinerman
Journal:  Cancer       Date:  2011-02-01       Impact factor: 6.860

2.  Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.

Authors:  Christopher I Li; Justin E Mirus; Yuzheng Zhang; Arturo B Ramirez; Jon J Ladd; Ross L Prentice; Martin W McIntosh; Samir M Hanash; Paul D Lampe
Journal:  Breast Cancer Res Treat       Date:  2012-08-19       Impact factor: 4.872

3.  Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study.

Authors:  Monika Holubova; Michaela Miklikova; Martin Leba; Daniel Georgiev; Pavel Jindra; Martin Caprnda; Rachele Ciccocioppo; Peter Kruzliak; Daniel Lysak
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-10       Impact factor: 4.553

4.  Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.

Authors:  Ashgan I El-Sarha; Gehan M Magour; Sameh M Zaki; Mohamed Y El-Sammak
Journal:  Pathol Oncol Res       Date:  2008-11-18       Impact factor: 3.201

5.  Study on apoptosis effect of human breast cancer cell MCF-7 induced by lycorine hydrochloride via death receptor pathway.

Authors:  Yubin Ji; Miao Yu; Zheng Qi; Di Cui; Guosong Xin; Bing Wang; Weiling Jia; Lin Chang
Journal:  Saudi Pharm J       Date:  2017-04-28       Impact factor: 4.330

6.  Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.

Authors:  Mohammad Hashemi; Aliakbar Fazaeli; Saeid Ghavami; Ebrahim Eskandari-Nasab; Farshid Arbabi; Mohammad Ali Mashhadi; Mohsen Taheri; Wiem Chaabane; Mayur V Jain; Marek J Łos
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

7.  Prognostic value of the Fas/Fas ligand system in breast cancer.

Authors:  Marek Bębenek; Danuta Duś; Joanna Koźlak
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.